# OnCo record nct07287917 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07287917/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07287917", "NCT07287917" ;
  schema:name "Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Eflornithine, Fulvestrant, Capivasertib in melanoma and skin cancer, run by Aminex Therapeutics, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07287917/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07287917> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2026-01-26" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:drugs <https://onco.cc/drugs/eflornithine/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/pembrolizumab/> .